Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer

被引:73
作者
Cho, Eun Jung [1 ]
Sun, Bo [1 ]
Doh, Kyung-Oh [1 ,2 ]
Wilson, Erin M. [1 ]
Torregrosa-Allen, Sandra [3 ]
Elzey, Bennett D. [3 ,4 ]
Yeo, Yoon [1 ,5 ]
机构
[1] Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA
[2] Yeungnam Univ, Coll Med, Dept Physiol, Taegu, South Korea
[3] Purdue Univ, W Lafayette, IN 47907 USA
[4] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA
[5] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA
基金
美国国家科学基金会;
关键词
Intraperitoneal chemotherapy; Drug delivery; Hyaluronic acid; Platinum; Ovarian cancer; Empty carriers; DRUG-DELIVERY; HUMAN MONOCYTES; PACLITAXEL; PERITONEAL; CISPLATIN; EXPRESSION; PHARMACOKINETICS; GROWTH; XENOGRAFTS; CD44S;
D O I
10.1016/j.biomaterials.2014.10.039
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Intraperitoneal (IP) chemotherapy is a promising post-surgical therapy of solid carcinomas confined within the peritoneal cavity, with potential benefits in locoregional and systemic management of residual tumors. In this study, we intended to increase local retention of platinum in the peritoneal cavity over a prolonged period of time using a nanoparticle form of platinum and an in-situ crosslinkable hyaluronic acid gel. Hyaluronic acid was chosen as a carrier due to the biocompatibility and biodegradability. We confirmed a sustained release of platinum from the nanoparticles (PtNPs) and nanoparticle/gel hybrid (PtNP/gel), receptor-mediated endocytosis of PtNPs, and retention of the gel in the peritoneal cavity over 4 weeks: conditions desirable for a prolonged local delivery of platinum. However, PtNPs and PtNP/gel did not show a greater anti-tumor efficacy than CDDP solution administered at the same dose but rather caused a slight increase in tumor burdens at later time points, which suggests a potential involvement of empty carriers and degradation products the growth of residual tumors: This study alerts that although several materials considered biocompatible and safe are used as drug carriers, they may have unwanted biological effects on the residual targets once the drug is exhausted; therefore, more attention should be paid to the selection of drug carriers. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:312 / 319
页数:8
相关论文
共 56 条
[1]   Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas [J].
Afify, AM ;
Ferguson, AW ;
Davila, RM ;
Werness, BA .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2001, 9 (04) :309-314
[2]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[3]   Hyaluronic acid-paclitaxel: Antitumor efficacy against CD44(+) human ovarian carcinoma xenografts [J].
Auzenne, Edmond ;
Ghosh, Sukhen C. ;
Khodadadian, Mojgan ;
Rivera, Belinda ;
Farquhar, David ;
Price, Roger E. ;
Ravoori, Murali ;
Kundra, Vikas ;
Freedman, Ralph S. ;
Klostergaard, Jim .
NEOPLASIA, 2007, 9 (06) :479-486
[4]   Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors [J].
Bajaj, Gaurav ;
Kim, Mi Ran ;
Mohammed, Sulma I. ;
Yeo, Yoon .
JOURNAL OF CONTROLLED RELEASE, 2012, 158 (03) :386-392
[5]   Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate [J].
Cai, Shuang ;
Xie, Yumei ;
Bagby, Taryn R. ;
Cohen, Mark S. ;
Forrest, M. Laird .
JOURNAL OF SURGICAL RESEARCH, 2008, 147 (02) :247-252
[6]   Pharmacokinetics and Disposition of a Localized Lymphatic Polymeric Hyaluronan Conjugate of Cisplatin in Rodents [J].
Cai, Shuang ;
Xie, Yumei ;
Davies, Neal M. ;
Cohen, Mark S. ;
Forrest, M. Laird .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (06) :2664-2671
[7]   CD44 VARIANT EXPRESSION IS A COMMON FEATURE OF EPITHELIAL OVARIAN-CANCER - LACK OF ASSOCIATION WITH STANDARD PROGNOSTIC FACTORS [J].
CANNISTRA, SA ;
ABUJAWDEH, G ;
NILOFF, J ;
STROBEL, T ;
SWANSON, L ;
ANDERSEN, J ;
OTTENSMEIER, C .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1912-1921
[8]   Cancer of the ovary [J].
Cannistra, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) :2519-2529
[9]   Phase I Trial of Intraperitoneal Pemetrexed, Cisplatin, and Paclitaxel in Optimally Debulked Ovarian Cancer [J].
Chambers, Setsuko K. ;
Chow, H-H. Sherry ;
Janicek, Mike F. ;
Cragun, Janiel M. ;
Hatch, Kenneth D. ;
Cui, Haiyan ;
Laughren, Cynthia ;
Clouser, Mary C. ;
Cohen, Janice L. ;
Wright, Heather M. ;
Abu Shahin, Nisreen ;
Alberts, David S. .
CLINICAL CANCER RESEARCH, 2012, 18 (09) :2668-2678
[10]   Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: Evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer [J].
Cho, Hyunah ;
Lai, Tsz Chung ;
Kwon, Glen S. .
JOURNAL OF CONTROLLED RELEASE, 2013, 166 (01) :1-9